Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR9 | P51686 | 5/20 | 0.55 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.44 |
| ▸ | CCR2 | P41597 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | FABP4 | P15090 | 2/20 | 0.42 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17684737 | 0.86 | AGTR1 (0.46) | CCR9PTGDR2KDM4E | |
| SCHEMBL15653992 | 0.85 | CCR9 (0.56) | CCR9PTGDR2CCR2 | |
| SCHEMBL17735991 | 0.84 | GPR35 (0.48) | CCR9PTGDR2KDM4EALDH1A1 | |
| SCHEMBL17684424 | 0.83 | CCR9 (0.61) | CCR9PTGDR2CCR2KDM4EFABP4 | |
| SCHEMBL28057475 | 0.79 | CCR9 (0.42) | CCR9PTGDR2KDM4EALDH1A1FABP4 | |
| SCHEMBL16304877 | 0.78 | AGTR1 (0.42) | CCR9PTGDR2KDM4EALDH1A1 | |
| SCHEMBL17684539 | 0.78 | CCR9 (0.56) | CCR9PTGDR2CCR2FABP4MDM2 | |
| SCHEMBL14476245 | 0.75 | MAPT (0.47) | CCR9PTGDR2KDM4EALDH1A1MDM2 | |
| SCHEMBL17684713 | 0.74 | PTGER4 (0.46) | MDM2 | |
| SCHEMBL17684710 | 0.74 | PTGER4 (0.46) | MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9855257-B2 | 4-alkynyl imidazole derivative and medicine comprising same as active ingredient | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2018-01-02 | — | — | US | disclosed |
| US-20170128431-A1 | 4-ALKYNYL IMIDAZOLE DERIVATIVE AND MEDICINE COMPRISING SAME AS ACTIVE INGREDIENT | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2017-05-11 | — | — | US | disclosed |
| US-20170128431-A1 | 4-ALKYNYL IMIDAZOLE DERIVATIVE AND MEDICINE COMPRISING SAME AS ACTIVE INGREDIENT | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2017-05-11 | — | — | US | disclosed |
| US-9593081-B2 | 4-alkynyl imidazole derivative and medicine comprising same as active ingredient | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2017-03-14 | — | — | US | disclosed |
| US-9593081-B2 | 4-alkynyl imidazole derivative and medicine comprising same as active ingredient | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2017-03-14 | — | — | US | disclosed |
| US-20160130232-A1 | 4-ALKYNYL IMIDAZOLE DERIVATIVE AND MEDICINE COMPRISING SAME AS ACTIVE INGREDIENT | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2016-05-12 | — | — | US | disclosed |
| US-20160130232-A1 | 4-ALKYNYL IMIDAZOLE DERIVATIVE AND MEDICINE COMPRISING SAME AS ACTIVE INGREDIENT | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2016-05-12 | — | — | US | disclosed |
| CN-105431416-A | 4-alkynyl imidazole derivative and medicine comprising same as active ingredient | KAKEN PHARMA CO LTD | 2016-03-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160130232-A1 | 4-ALKYNYL IMIDAZOLE DERIVATIVE AND MEDICINE COMPRISING SAME AS ACTIVE INGREDIENT | PTGER4, IL4, PTGER1 | CCR9 114/4885PTGDR2 33/4885CCR2 191/4885 |
| US-20170128431-A1 | 4-ALKYNYL IMIDAZOLE DERIVATIVE AND MEDICINE COMPRISING SAME AS ACTIVE INGREDIENT | PTGER4, IL4, PTGER1 | CCR9 83/4885PTGDR2 26/4885CCR2 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.